Skip to content

Discussion on the clinical efficacy and mechanism of the treatment of chronic heart failure of the type of qi and yin deficiency and yang deficiency and blood stasis by the Sheng mai jiu xin Tang

Discussion on the clinical efficacy and mechanism of the treatment of chronic heart failure of the type of qi and yin deficiency and yang deficiency and blood stasis by the Sheng mai jiu xin Tang

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000144
Enrollment
Unknown
Registered
2025-01-16
Start date
2023-06-01
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Interventions

Experimental group Group:In the experimental group, on the basis of the conventional treatment of Western medicine, the addition of Sheng Maijiuxintang
Control Group:According to the 2018 Chinese Guidelines for the Diagnosis and Treatment of Heart Failure, conventional Western treatment involves blood pressure control in hypertensive patients, blood

Sponsors

Wuxi Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Traditional Chinese Medicine China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 95 Years

Inclusion criteria

Inclusion criteria: (1) aged 18 years or older gender is not limited; (2) meet the diagnostic criteria of ADHF; (3) meet the Chinese medicine diagnostic criteria of heart failure disease with qi and yin deficiency and yang deficiency and blood stasis; (4) NYHA cardiac function class III-IV; (5) LVEF = 49%; (6) have informed understanding of the study and sign the informed consent for the trial; and (7) have good adherence to the follow up. Translated with www.DeepL.com/Translator (free version)

Exclusion criteria

Exclusion criteria: (1) myocardial infarction or unstable angina within 1 month; (2) severe hepatic and renal insufficiency (glomerular filtration rate (eGFR) 120 U/L); (3) systolic blood pressure <80 mmHg with hypoperfusion or cardiogenic shock; (4) women in preparation for pregnancy during pregnancy or during breastfeeding; (5) suffering from other serious diseases malignant tumor severe hyperthyroidism severe infection severe anemia high degree of atrioventricular block severe valvular disease of the heart etc.; (6) patients with clear contraindications to the experimental underlying Western therapeutic drugs; (7) patients who participated in other clinical trials during the observation period.

Design outcomes

Primary

MeasureTime frame
Human hypoxia-inducible factor 1 alpha;N-terminal brain natriuretic peptide precursor;Human cystatinase 3;Human vascular endothelial growth factor A;left ventricular ejection fraction;Heart Function Classification (NYHA Classification);

Secondary

MeasureTime frame
Chinese medicine evidence points;Comparison of the number of heart failure hospitalizations at 1 month post-discharge;Chinese medicine evidence efficacy;6-minute walking distance;

Countries

China

Contacts

Public Contactzhao yang

Wuxi Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Traditional Chinese Medicine China

wxzy004@njucm.edu.cn18861625981

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026